Abstract 401P
Background
Academic field in oncology is male dominated in India as it is in the rest of the world. There is a dearth of female oncologists in managerial or leadership posts in oncology. Female oncologists face unique challenges in this field. Female authorship as first or corresponding author is a surrogate marker for the representation of females in the academic world. This study was undertaken to determine the extent of female participation/leadership in oncology in India.
Methods
An online survey was conducted across the women in the field of oncology in India. Also, the issues of Indian Journal of Cancer and Indian Journal of Medical and Paediatric Oncology from January 2017 to December 2018 were examined. The articles with female first or corresponding authors were enumerated.
Results
Of the 153 participants in the survey, 56% were above 40 years of age. 53% of them were clinical oncologists. 65% of the females worked in male majority teams and 67% admitted to working with male managers. Only 31% of the respondents covered a leadership role within their jobs. Family commitments, perception of males as the natural leaders and maintaining a work family balance were quoted to be the most frequent obstacles to career progression. A total of 558 journal publications were inspected. Of these, 145 articles (26%) had a female first author or a corresponding author, of which 94 (64.9%) were original articles. Each issue had a median of 30 publications, of which median of 8 publications (range 3-15) were authored by females. Of the 360 original articles perused, only 94 (26.1%) had female authorship.
Conclusions
This study was undertaken to analyse the participation of females in oncology and allied sciences in India. Only 1/3 of the females were in a leadership position of the 153 survey participants. Majority of the females work in male-dominated work environments and tackle multitude of impediments in advancement in their profession. Objectively, only 26% of the publications in two of the leading oncology journals of India were authored by females. Female first/corresponding authors were found only in 26% of the original articles. More efforts are to be taken for women empowerment and increase the representation of females in this field. More flexible work/training schedules are required for their upliftment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract